At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 206 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Tirzepatide Monotherapy Compared With Placebo in Chinese Participants With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating Tirzepatide and Placebo for Type 2 Diabetes. Completed, enrolled 206 participants across 28 sites.
Detailed Summary
The main purpose of this study is to investigate the efficacy and safety of Tirzepatide monotherapy in Chinese participants with Type 2 Diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
202420252026
First PostedJul 2023
Enrollment StartAug 2023
Primary CompletionOct 2024
TodayJul 2026
First PostedJul 27, 2023
Enrollment StartAug 21, 2023
Primary CompletionOct 9, 2024
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 2.9 years ago
Interventions
Tirzepatidedrug
Administered SC
Placebodrug
Administered SC